Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-year to Rs 2,206 crore, while net profit more than doubled to Rs 441 crore. Growth was supported by sustained momentum in its CDMO business and Affordable Medicines division, alongside improving margins and continued investments in manufacturing capabilities.
Key Takeaways
- Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results.
- Revenue increased 33% year-on-year to Rs 2,206 crore, while net profit more than doubled to Rs 441 crore.
- Growth was supported by sustained momentum in its CDMO business and Affordable Medicines division, alongside improving margins and continued investments in manufacturing capabilities.
Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-year to Rs 2,206 crore, while net profit more than doubled to Rs 441 crore. Growth was supported by sustained momentum in its CDMO business and Affordable Medicines division, alongside improving margins and continued investments in manufacturing capabilities.
Original Publisher Attribution
This summary was curated from Economic Times.